Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 36 results
Filters: First Letter Of Last Name is R  [Clear All Filters]
Found 36 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

R

Raboud JM, Diong C, Carr A, et al. "A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy." HIV Clin Trials. 2010;11(1):39-50.
Ranade K, Geese WJ, Noor M, et al. "Genetic analysis implicates resistin in HIV lipodystrophy." AIDS. 2008;22(13):1561-8.
Reynolds NR, Sun J, Nagaraja HN, Gifford AL, Wu AW, Chesney MA. "Optimizing measurement of self-reported adherence with the ACTG Adherence Questionnaire: a cross-protocol analysis." J. Acquir. Immune Defic. Syndr.. 2007;46(4):402-9.
Reynolds NR, Neidig JL, Wu AW, Gifford AL, Holmes WC. "Balancing disfigurement and fear of disease progression: Patient perceptions of HIV body fat redistribution." AIDS Care. 2006;18(7):663-73.
Reynolds NR, Testa MA, Su M, et al. "Telephone support to improve antiretroviral medication adherence: a multisite, randomized controlled trial." J. Acquir. Immune Defic. Syndr.. 2008;47(1):62-8.
Rhee S-Y, Kantor R, Katzenstein DA, et al. "HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes." AIDS. 2006;20(5):643-51.
Ribaudo HJ, Daar ES, Tierney C, et al. "Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202." J. Infect. Dis.. 2013;207(3):420-5.
Ribaudo HJ, Kuritzkes DR, Schackman BR, Acosta EP, Shikuma CM, Gulick RM. "Design issues in initial HIV-treatment trials: focus on ACTG A5095." Antivir. Ther. (Lond.). 2006;11(6):751-60.
Ribaudo HJ, Liu H, Schwab M, et al. "Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study." J. Infect. Dis.. 2010;202(5):717-22.
Ribaudo HJ, Haas DW, Tierney C, et al. "Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study." Clin. Infect. Dis.. 2006;42(3):401-7.
Ribaudo HJ, Kuritzkes DR, Gulick RM. "A comparison of three initial antiretroviral AIDS regimens." N. Engl. J. Med.. 2007;357(10):1056-7.
Ribaudo HJ, Smith KY, Robbins GK, et al. "Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysis." Clin. Infect. Dis.. 2013;57(11):1607-17.
Ribaudo HJ, Benson CA, Zheng Y, et al. "No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT." Clin. Infect. Dis.. 2011;52(7):929-40.
Ribaudo HJ, Kuritzkes DR, Lalama CM, et al. "Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts." J. Infect. Dis.. 2008;197(7):1006-10.
Richman DD. "Antiviral drug resistance." Antiviral Res.. 2006;71(2-3):117-21.
Riddler SA, Haubrich R, A DiRienzo G, et al. "Class-sparing regimens for initial treatment of HIV-1 infection." N. Engl. J. Med.. 2008;358(20):2095-106.
Riddler SA, Jiang H, Tenorio A, et al. "A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115." Antivir. Ther. (Lond.). 2007;12(4):531-41.
Riddler SA, Aga E, Bosch RJ, et al. "Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy." J. Infect. Dis.. 2016;213(4):556-60.
Robbins GK, Spritzler JG, Chan ES, et al. "Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384." Clin. Infect. Dis.. 2009;48(3):350-61.
Robbins GK, Testa MA, Su M, et al. "Site nurse-initiated adherence and symptom support telephone calls for HIV-positive individuals starting antiretroviral therapy, ACTG 5031: substudy of ACTG 384." HIV Clin Trials. 2013;14(5):235-53.
Robbins GK, Cohn SE, Harrison LJ, et al. "Characteristics associated with virologic failure in high-risk HIV-positive participants with prior failure: a post hoc analysis of ACTG 5251." HIV Clin Trials. 2016;17(4):165-72.
Robertson K, Kopnisky K, Hakim J, et al. "Second assessment of NeuroAIDS in Africa." J. Neurovirol.. 2008;14(2):87-101.
Robertson KR, Miyahara S, Lee A, et al. "Neurocognition in maraviroc- compared to tenofovir: a double blind randomized placebo controlled trial ACTG A5303." AIDS. 2016.
Robertson K, Kumwenda J, Supparatpinyo K, et al. "A multinational study of neurological performance in antiretroviral therapy-naïve HIV-1-infected persons in diverse resource-constrained settings." J. Neurovirol.. 2011;17(5):438-47.
Robertson K, Jiang H, Kumwenda J, et al. "Improved neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group study a5199, the International Neurological Study." Clin. Infect. Dis.. 2012;55(6):868-76.
Robertson KR, Smurzynski M, Parsons TD, et al. "The prevalence and incidence of neurocognitive impairment in the HAART era." AIDS. 2007;21(14):1915-21.
Robertson KR, Su Z, Margolis DM, et al. "Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort." Neurology. 2010;74(16):1260-6.
Robertson K, Jiang H, Evans SR, et al. "International neurocognitive normative study: neurocognitive comparison data in diverse resource-limited settings: AIDS Clinical Trials Group A5271." J. Neurovirol.. 2016;22(4):472-8.
Rockwood N, Meintjes G, Chirehwa M, et al. "HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients." Antimicrob. Agents Chemother.. 2016;60(10):6050-9.
Rodriguez B, Lederman MM, Jiang W, et al. "Interferon-alpha differentially rescues CD4 and CD8 T cells from apoptosis in HIV infection." AIDS. 2006;20(10):1379-89.

Pages